Weiss Ratings Reiterates Sell (E+) Rating for Arvinas (NASDAQ:ARVN)

Key Points

• Weiss Ratings has reiterated a "sell (e+)" rating for Arvinas, highlighting concerns about the company's stock performance.
• Arvinas recently reported a negative net margin of 19.47% and a significant year-over-year revenue decline of 70.7%.
• Despite mixed ratings from various analysts, Arvinas has seen substantial institutional investment increases, with some entities boosting their holdings by over 900%.

Arvinas (NASDAQ:ARVN - Get Free Report)'s stock had its "sell (e+)" rating reiterated by stock analysts at Weiss Ratings in a report released on Friday,Weiss Ratings reports.

Several other research firms also recently issued reports on ARVN. Barclays started coverage on shares of Arvinas in a research note on Wednesday, September 17th. They issued an "overweight" rating and a $16.00 price objective for the company. HC Wainwright decreased their price objective on shares of Arvinas from $24.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Wedbush restated a "neutral" rating and issued a $9.00 price objective (down previously from $10.00) on shares of Arvinas in a research note on Thursday, September 18th. Piper Sandler restated an "overweight" rating and issued a $16.00 price objective on shares of Arvinas in a research note on Tuesday, October 7th. Finally, Wells Fargo & Company decreased their price objective on shares of Arvinas from $19.00 to $16.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Arvinas presently has a consensus rating of "Hold" and an average target price of $16.18.

Arvinas Trading Up 0.5%

Shares of ARVN stock traded up $0.05 on Friday, reaching $9.21. 3,455,619 shares of the stock were exchanged, compared to its average volume of 2,168,218. The business's 50 day moving average price is $8.31 and its 200 day moving average price is $7.73. The company has a market capitalization of $676.20 million, a price-to-earnings ratio of -9.12 and a beta of 2.39. Arvinas has a twelve month low of $5.90 and a twelve month high of $29.61.

Arvinas (NASDAQ:ARVN - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.84) EPS for the quarter, topping analysts' consensus estimates of ($0.87) by $0.03. The firm had revenue of $22.40 million during the quarter, compared to the consensus estimate of $34.42 million. Arvinas had a negative net margin of 19.47% and a negative return on equity of 12.01%. The company's revenue was down 70.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.49) earnings per share. Equities research analysts forecast that Arvinas will post -3.81 earnings per share for the current year.

Arvinas announced that its Board of Directors has authorized a stock repurchase program on Wednesday, September 17th that allows the company to buyback $100.00 million in shares. This buyback authorization allows the company to buy up to 17.9% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's board believes its shares are undervalued.

Insider Transactions at Arvinas

In other news, Director Briggs Morrison purchased 30,000 shares of the business's stock in a transaction that occurred on Monday, September 22nd. The stock was purchased at an average cost of $7.57 per share, with a total value of $227,100.00. Following the completion of the acquisition, the director directly owned 76,021 shares of the company's stock, valued at approximately $575,478.97. This trade represents a 65.19% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.73% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd raised its holdings in Arvinas by 965.4% during the first quarter. Caitong International Asset Management Co. Ltd now owns 4,656 shares of the company's stock worth $33,000 after purchasing an additional 4,219 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Arvinas by 491.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company's stock worth $43,000 after purchasing an additional 4,835 shares in the last quarter. Canada Pension Plan Investment Board increased its holdings in Arvinas by 109.4% in the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company's stock valued at $49,000 after buying an additional 3,500 shares in the last quarter. CWM LLC increased its holdings in Arvinas by 2,317.5% in the first quarter. CWM LLC now owns 7,615 shares of the company's stock valued at $53,000 after buying an additional 7,300 shares in the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new position in Arvinas in the second quarter valued at about $74,000. 95.19% of the stock is owned by hedge funds and other institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.